title: Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report.
abstract: Behçet's disease (BD) is a multisystem disorder characterized by vasculitis. Pulmonary vascular problems such as pulmonary artery aneurysms (PAA) are reported to indicate poor prognosis and high mortality. We describe a 43-year-old man who presented with life threatening bilateral PAA and thromboembolic disease due to BD. He was treated with prednisone and pulse cyclophosphamide and was poorly responsive to the conventional immunosuppression. The introduction of adalimumab therapy stabilized his PAA. We report that the inhibition of TNF-alpha using the neutralizing monoclonal antibody adalimumab has the potential to induce rapid, complete, and long-lasting remission in a life-threatening manifestation of BD.
authors.affiliation: Department of Internal Medicine, Dong-A University, College of Medicine, Busan, Korea. leesw@dau.ac.kr
authors.forename: Sung-Won
authors.initials: SW
authors.lastname: Lee
authors.forename: Sang-Yeob
authors.initials: SY
authors.lastname: Lee
authors.forename: Ki-Nam
authors.initials: KN
authors.lastname: Kim
authors.forename: Jin-Kyu
authors.initials: JK
authors.lastname: Jung
authors.forename: Won-Tae
authors.initials: WT
authors.lastname: Chung
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000783:Aneurysm / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D000068879:Adalimumab; D011241:Prednisone